Oxandrolone
| Subclass of | Anavar  |
|---|---|
| Get use | Medication |
| Stereoisomer of | (1S,3aR,3bR,5aS,9aS,9bR,11aS)-1-hydroxy-1,9a,11a-trimethyl-2,3,3a,3b,4,5,5a,6,9,9b,10,11-dodecahydroindeno[4,5-h]isochromen-7-one, 17-epioxandrolone |
| Chemical formula | C₁₉H₃₀O₃ |
| Canonical SMILES | CC12CCC3C(C1CCC2(C)O)CCC4C3(COC(=O)C4)C |
| Isomeric SMILES | C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C)O)CC[C@@H]4[C@@]3(COC(=O)C4)C |
| World Health Organisation international non-proprietary name | oxandrolone |
| Medical condition treated | failure to thrive |
| Legal status (medicine) | boxed warning |
| Subject has role | androgen, anabolic |
Oxandrolone be an androgen den synthetic anabolic steroid (AAS) medication to help promote weight gain insyd various situations, to help offset protein catabolism wey long-term corticosteroid therapy cause, to support recovery from severe burns, to treat bone pain dem associate plus osteoporosis, to aid insyd de development of girlies plus Turner syndrome, den give oda indications.[1][2][3] Dem dey take am by mouth.[1] Dem dey sell am under de brand names Oxandrin den Anavar, among odas.[4]
De drug be a synthetic androgen den anabolic steroid, hence e be an agonist of de androgen receptor (AR), de biological target of androgens such as testosterone den dihydrotestosterone.[1][5] Side effects of oxandrolone dey include severe cases of peliosis hepatis, sam times dem associate plus liver failure den intra-abdominal hemorrhage; liver tumors, sam times fatal; den blood lipid changes dem associate plus increased risk of atherosclerosis. Additional warnings dey include de risks dem associate plus cholestatic hepatitis, hypercalcemia insyd patients plus breast cancer, den increased risk for de development of prostatic hypertrophy den prostatic carcinoma insyd older patients.[6] E get strong anabolic effects den weak androgenic effects, wich give am a mild side effect profile in dat regard wey e make am especially suitable for use insyd women.[1] Milder side effects insyd women be increased sexual desire, symptoms of hyperandrogenism such as acne, den symptoms of masculinization such as increased hair growth den voice changes.[1]
Na dem describe oxandrolone first insyd 1962 wey dem introduce am for medical use insyd 1964.[1] De drug be a controlled substance insyd chaw countries, so non-medical use for purposes such as improving physique den performance be generally illicit.[1][7][8][9][10]
Insyd de United States, de FDA ein Endocrinologic and Metabolic Drugs Advisory Committee unanimously conclude insyd 1984 say der be no evidence of efficacy give oxandrolone.[11] On March 26, 2019, Gemini biz FDA to withdraw approval for all doses of de drug, dey state say dem no longer dey market am.[6][11] FDA notify Gemini den oda license holders on December 16, 2022, say e believe say de potential problems plus de drug say na de drug be sufficiently serious say e for be removed from de market, dey cite de 1984 finding of lack of efficacy den de extensive safety warnings den precautions dem list on de prescribing information, "wey dey include peliosis hepatis, sam times dem associate plus liver failure den intra-abdominal hemorrhage; liver cell tumors, sam times fatal; den blood lipid changes wey be known to be associated plus increased risk of atherosclerosis" as well as "cholestatic hepatitis, hypercalcemia in patients plus breast cancer, den increased risk give de development of prostatic hypertrophy den prostatic carcinoma insyd geriatric patients."[11] Gemini den Sandoz request say de FDA completely withdraw approval give de drug.[11]
References
[edit | edit source]- 1 2 3 4 5 6 7 Llewellyn W (2011). Anabolics. Molecular Nutrition Llc. pp. 342–352. ISBN 978-0-9828280-1-4. Archived from the original on 2024-04-07. Retrieved 2017-11-06.
- ↑ Li H, Guo Y, Yang Z, Roy M, Guo Q (June 2016). "The efficacy and safety of oxandrolone treatment for patients with severe burns: A systematic review and meta-analysis". Burns. 42 (4): 717–727. doi:10.1016/j.burns.2015.08.023. PMID 26454425. S2CID 24139354.
- ↑ Rojas Y, Finnerty CC, Radhakrishnan RS, Herndon DN (December 2012). "Burns: an update on current pharmacotherapy". Expert Opinion on Pharmacotherapy. 13 (17): 2485–2494. doi:10.1517/14656566.2012.738195. PMC 3576016. PMID 23121414.
- ↑ Mavros, Yorgi; O'Neill, Evelyn; Connerty, Maureen; Bean, Jonathan F.; Broe, Kerry; Kiel, Douglas P.; Maclean, David; Taylor, Ann; Fielding, Roger A.; Singh, Maria A. Fiatarone (November 2015). "Oxandrolone Augmentation of Resistance Training in Older Women: A Randomized Trial". Medicine and Science in Sports and Exercise. 47 (11): 2257–2267. doi:10.1249/MSS.0000000000000690. ISSN 1530-0315. PMID 25899102.
- ↑ Kicman AT (June 2008). "Pharmacology of anabolic steroids". British Journal of Pharmacology. 154 (3): 502–521. doi:10.1038/bjp.2008.165. PMC 2439524. PMID 18500378.
- 1 2 FDA (2023-09-13). "Determination That Oxandrin (Oxandrolone) Tablets, 2.5 Milligrams and 10 Milligrams, Were Withdrawn From Sale for Reasons of Safety or Effectiveness" (PDF). federalregister.gov. Archived (PDF) from the original on 2024-03-18. Retrieved 2024-03-18.
- ↑ Korkia P, Stimson GV (October 1997). "Indications of prevalence, practice and effects of anabolic steroid use in Great Britain". International Journal of Sports Medicine. 18 (7): 557–562. doi:10.1055/s-2007-972681. PMID 9414081. S2CID 260169851.
Low dose 28 +/- 18; High dose 80 +/- 13
- ↑ "Controlled Substances Act". United States Food and Drug Administration. 11 June 2009. Archived from the original on 2 March 2017. Retrieved 17 June 2016.
- ↑ Legislative Services Branch. "Consolidated federal laws of Canada, Controlled Drugs and Substances Act=". laws-lois.justice.gc.ca. Archived from the original on 2017-02-05. Retrieved 2017-01-14.
- ↑ "List of most commonly encountered drugs currently controlled under the misuse of drugs legislation - GOV.UK". www.gov.uk. Archived from the original on 2019-12-08. Retrieved 2017-01-14.
- 1 2 3 4 "Gemini Laboratories, LLC, et al.; Withdrawal of Approval of One New Drug Application for OXANDRIN (Oxandrolone) Tablets and Four Abbreviated New Drug Applications for Oxandrolone Tablets". Federal Register. Office of the Federal Register of the National Archives and Records Administration. 28 June 2023. Retrieved 1 January 2025.
External links
[edit | edit source]
- Oxandrin Homepage, savientpharma.com (via archive.org)
- Oxandrin Label, fda.gov (retrieved 23 October 2009)
- "Oxandrolone Side Effects, Interactions and Information". drugs.com.